NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

So ultimately, its tumor size. In metastatic patients or patients with multiple tumors, the reason not all tumors can be injected is because some are either too small to be seen (aka: 'occult') and/or too small to inject. If that is the case, then there will not be any ethics issues in this trial when systemic response is looked at in patients where not all tumors are injected. This is helpful.

Therefore, I am wondering how scientists will detect systemic response in these small tumors that are hard to see….I assume they will use various clinical means, including some types of chemical tracers?

I agree this goes to the heart of systemic treatment, and as a former cancer patient ( I was not metastatic) I can empathize with patients and doctors who would not want to be in the O.R. for a ridiculous amount of time trying to make certain every last tumor was injected….which they could not ever be sure of anyway.

Note: I'm writing as if I found the answer (by your lead), but I'm still "sleuthing" here….